Fludarabine (NSC 118218)

For research use only. Not for use in humans.

目录号：S1491 别名： FaraA, Fludarabinum 中文名称：氟达拉滨

Fludarabine (NSC 118218) Chemical Structure

CAS No. 21679-14-1

Fludarabine (NSC 118218, FaraA, Fludarabinum)在血管平滑肌细胞中是一种STAT1活化抑制剂，特异性降低STAT1蛋白质水平（和mRNA水平），而对其他STATs无此作用。它还是一种DNA合成抑制剂。Fludarabine可诱导凋亡。

规格

价格

库存

购买数量

10mM (1mL in DMSO)	RMB 1032.75	现货
10mg	RMB 810.59	现货
50mg	RMB 2525.07	现货
100mg	RMB 3836.33	现货
200mg	RMB 7289.1	现货
大包装	有超大折扣

大剂量询单有大折扣!

今日订购，明日送达，全国免运费！

全国免费电话：400-668-6834 | Email：info@selleck.cn

客户使用Selleck生产的Fludarabine (NSC 118218)发表文献103篇：

Cell, 2020, 182(3):685-712.e19

PubMed: 32645325 ( click the link to review the publication )

Cell Metab, 2020, 31(3):564-579

PubMed: 32130883 ( click the link to review the publication )

Nat Chem Biol, 2018, 14(10):943-954

PubMed: 30150681 ( click the link to review the publication )

Cancer Cell, 2018, 34(5):757-774

PubMed: 30423296 ( click the link to review the publication )

Cell Rep, 2021, 34(1):108584

PubMed: 33406422 ( click the link to review the publication )

Aging (Albany NY), 2021, 13(8):12160-12178

PubMed: 33901014 ( click the link to review the publication )

Lab Invest, 2021, 10.1038/s41374-021-00618-1

PubMed: 34108631 ( click the link to review the publication )

Ann Transl Med, 2021, 9(5):365

PubMed: 33842586 ( click the link to review the publication )

Life Sci, 2021, S0024-3205(21)00637-8

PubMed: 34048810 ( click the link to review the publication )

Clinics (Sao Paulo), 2021, 76:e2348

PubMed: 33681944 ( click the link to review the publication )

Liver Int, 2021, 10.1111/liv.14816

PubMed: 33555112 ( click the link to review the publication )

Cell Res, 2020, 1-10

PubMed: 33159154 ( click the link to review the publication )

Sci Adv, 2020, 29;6(18):eaax7881

PubMed: 32494661 ( click the link to review the publication )

Cell Rep, 2020, 31(13):107825

PubMed: 32610126 ( click the link to review the publication )

Haematologica, 2020, 16 pii: haematol

PubMed: 32299906 ( click the link to review the publication )

J Exp Clin Cancer Res, 2020, 39(1):228

PubMed: 33115525 ( click the link to review the publication )

Br J Cancer, 2020, 18

PubMed: 32418995 ( click the link to review the publication )

Signal Transduct Target Ther, 2020, 5(1):34

PubMed: 32296043 ( click the link to review the publication )

Signal Transduct Target Ther, 2020, 10;5:34

PubMed: 32284883 ( click the link to review the publication )

Cell Chem Biol, 2020, 27(1):122-133

PubMed: 31836351 ( click the link to review the publication )

Front Immunol, 2020, 14;11:867

PubMed: 32477351 ( click the link to review the publication )

Cell Commun Signal, 2020, 18(1):30

PubMed: 32093731 ( click the link to review the publication )

Exp Neurol, 2020, S0014-4886(20)30337-X

PubMed: 33065077 ( click the link to review the publication )

Cancer Cell Int, 2020, 19;20:58

PubMed: 32099531 ( click the link to review the publication )
Life Sci, 2020, 265:118832

PubMed: 33259866 ( click the link to review the publication )

Cardiovasc Diagn Ther, 2020, 10(4):738-751

PubMed: 32968630 ( click the link to review the publication )

Scand J Immunol, 2020, e12981

PubMed: 33031600 ( click the link to review the publication )

Hum Cell, 2020, 10.1007/s13577-020-00425-8

PubMed: 32886306 ( click the link to review the publication )

Hum Cell, 2020, 10.1007/s13577-020-00420-z

PubMed: 32870449 ( click the link to review the publication )

Clin Exp Pharmacol Physiol, 2020, 4

PubMed: 32248559 ( click the link to review the publication )

Exp Lung Res, 2020, 1-9

PubMed: 33238771 ( click the link to review the publication )

J Cancer Res Clin Oncol, 2020, 146(2):329-342

PubMed: 31912229 ( click the link to review the publication )

PLoS One, 2020, 15(7):e0228302

PubMed: 32628668 ( click the link to review the publication )

Int J Cancer, 2020, 10.1002/ijc.33202

PubMed: 32638373 ( click the link to review the publication )

Front Immunol, 2020, 11:1303

PubMed: 32655571 ( click the link to review the publication )

Microb Pathog, 2020, 142:104112

PubMed: 32126255 ( click the link to review the publication )

Int J Biol Macromol, 2020, 147:616-628

PubMed: 31931060 ( click the link to review the publication )

Cell Mol Immunol, 2020, 10.1038/s41423-019-0345-7

PubMed: 31900460 ( click the link to review the publication )

Cancer Immunol Res, 2020, 8(3):292-308

PubMed: 32024640 ( click the link to review the publication )

J Microbiol Immunol Infect, 2020, 25 pii: S1684-1182(20)30001-3

PubMed: 32033858 ( click the link to review the publication )

Stem Cell Res Ther, 2020, 11(1):112

PubMed: 32169104 ( click the link to review the publication )

Blood, 2019, 134(21):1821-1831

PubMed: 31527074 ( click the link to review the publication )

Nat Chem Biol, 2019, 15(3):232-240

PubMed: 30692684 ( click the link to review the publication )

Nat Commun, 2019, 10(1):2189

PubMed: 31097698 ( click the link to review the publication )

Mucosal Immunol, 2019, 10.1038/s41385-019-0178-9

PubMed: 31182817 ( click the link to review the publication )

Redox Biol, 2019, 24:101189

PubMed: 30986607 ( click the link to review the publication )

Cancer Lett, 2019, 10.1016/j.canlet.2019.07.016

PubMed: 31352079 ( click the link to review the publication )

PLoS Pathog, 2019, 15(11):e1008037

PubMed: 31725811 ( click the link to review the publication )
Mol Ther Oncolytics, 2019,

PubMed: 30775418 ( click the link to review the publication )

Front Immunol, 2019, 10:1622

PubMed: 31379827 ( click the link to review the publication )

Am J Cancer Res, 2019, 9(12):2618-2633

PubMed: 31911850 ( click the link to review the publication )

J Immunol, 2019, 202(11):3173-3186

PubMed: 30996000 ( click the link to review the publication )

Int J Biol Macromol, 2019, 136:980-993

PubMed: 31220493 ( click the link to review the publication )

Respir Res, 2019, 20(1):184

PubMed: 31416461 ( click the link to review the publication )

Life Sci, 2019, 10.1016/j.lfs.2019.116583

PubMed: 31226417 ( click the link to review the publication )

Gut Pathog, 2019, 11:23

PubMed: 31123503 ( click the link to review the publication )

Immunobiology, 2019, 224(3):388-396

PubMed: 30846331 ( click the link to review the publication )

Appl Health Econ Health Policy, 2019, 17(6):827-839

PubMed: 31392669 ( click the link to review the publication )

J Microbiol Immunol Infect, 2019, S1684-1182(18)30306-2

PubMed: 31296484 ( click the link to review the publication )

Cancer Immunol Res, 2019, 7(12):1944-1957

PubMed: 31554639 ( click the link to review the publication )

Hepatology, 2018, 10.1002/hep.30317

PubMed: ( click the link to review the publication )

J Cell Biol, 2018, 217(4):1503-1519

PubMed: 29507126 ( click the link to review the publication )

Mol Syst Biol, 2018, 14(3):e7858

PubMed: 29507054 ( click the link to review the publication )

Oncogene, 2018, 37(17):2270-2284

PubMed: 29391602 ( click the link to review the publication )

Cell Death Dis, 2018, 9(5):459

PubMed: 29686406 ( click the link to review the publication )

Br J Cancer, 2018, 118(4):509-521

PubMed: 29348488 ( click the link to review the publication )

Expert Opin Ther Targets, 2018, 22(6):547-557

PubMed: 29702007 ( click the link to review the publication )

J Virol, 2018, 92(22)e00728-18

PubMed: 30185587 ( click the link to review the publication )

Hum Immunol, 2018, 79(12):869-875

PubMed: 30316971 ( click the link to review the publication )

Oncotarget, 2018, 9(10):9273-9284

PubMed: 29507689 ( click the link to review the publication )

Neuron, 2017, 96(6):1290-1302

PubMed: 29268096 ( click the link to review the publication )

Nat Commun, 2017, 8:15207

PubMed: 28488695 ( click the link to review the publication )
Nat Commun, 2017, 8:15776

PubMed: 28585539 ( click the link to review the publication )

Leukemia, 2017, 31(2):340-349

PubMed: 27431016 ( click the link to review the publication )

Cancer Res, 2017, 77(15):4135-4145

PubMed: 28615225 ( click the link to review the publication )

Brain Behav Immun, 2017, 60:161-173

PubMed: 27742579 ( click the link to review the publication )

Mol Cancer Res, 2017, 15(5):585-597

PubMed: 28108623 ( click the link to review the publication )

Sci Rep, 2017,

PubMed: 29259270 ( click the link to review the publication )

Sci Rep, 2017, 7(1):14416

PubMed: 29089548 ( click the link to review the publication )

Clin Immunol, 2017, 175:56-68

PubMed: 27940139 ( click the link to review the publication )

J Cell Biochem, 2017, 118(10):3249-3259

PubMed: 28262979 ( click the link to review the publication )

Inflammation, 2017, 40(5):1726-1734

PubMed: 28656529 ( click the link to review the publication )

Mol Med Rep, 2017, 16(6):9111-9119

PubMed: 28990062 ( click the link to review the publication )

PLoS One, 2017, 12(6):e0180244

PubMed: 28665978 ( click the link to review the publication )

J Clin Invest, 2016, 126(1):181-94

PubMed: 26619119 ( click the link to review the publication )

J Exp Med, 2016, 19;213(10):2209-26

PubMed: 27621415 ( click the link to review the publication )

Cancer Res, 2016, 76(4):818-30

PubMed: 26837767 ( click the link to review the publication )

Int Immunopharmacol, 2016, 36:199-204

PubMed: 27160867 ( click the link to review the publication )

FEBS Lett, 2016, 590(1):53-67

PubMed: 26762170 ( click the link to review the publication )

Biogerontology, 2016, 17(5-6):907-920

PubMed: 27484416 ( click the link to review the publication )

Oncotarget, 2016, 8(31):50570-50581

PubMed: 28881584 ( click the link to review the publication )

EMBO Mol Med, 2015, 10.15252/emmm.201404580

PubMed: 25759362 ( click the link to review the publication )

Eur J Immunol, 2015, 45(10):2834-46

PubMed: 26255980 ( click the link to review the publication )

Phytother Res, 2015, 29(7):1088-96

PubMed: 25881570 ( click the link to review the publication )

Int Immunopharmacol, 2015, 28(1):61-9

PubMed: 26044347 ( click the link to review the publication )

Mol Med Rep, 2015, 12(6):7869-76

PubMed: 26497667 ( click the link to review the publication )
Oncotarget, 2015, 6(41):43992-4004

PubMed: 26556857 ( click the link to review the publication )

Basic Res Cardiol, 2014, 109(4):419

PubMed: 24907869 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1512

PubMed: 25375377 ( click the link to review the publication )

Mol Cancer Ther, 2014, 13(10):2276-87

PubMed: 25122069 ( click the link to review the publication )

J Biol Chem, 2014, 289(14):9952-60

PubMed: 24550394 ( click the link to review the publication )

Mol Cell Biol, 2014, 34(24):4368-78

PubMed: 25312644 ( click the link to review the publication )

Mol Cancer Ther, 2013, 12(7):1299-309

PubMed: 23657945 ( click the link to review the publication )

产品安全说明书

STAT抑制剂选择性比较

生物活性

产品描述

靶点

STAT1 ^[4]
(Vascular smooth muscle cells)

体外研究

Fludarabine有效抑制RPMI8226细胞增殖,呈时间浓度依赖性。Fludarabine处理MM.1S和MM.1R细胞48小时的IC50分别为13.48μg/mL和33.79μg/mL。而Fludarabine处理U266细胞48小时的IC 50为222.2μg/mL。Fludarabine处理可增加处于细胞周期G 1期的细胞数量，并伴随着处于细胞周期S期细胞数量的减少，对细胞周期的影响呈时间依赖性。Fludarabine在MM细胞中诱导细胞周期阻滞和细胞凋亡。Fludarabine时间依赖性的诱导caspase，-8，- 9和- 3，- 7的剪切，继而诱导PARP的剪切。氟达拉滨以时间梯度增加Bax基因表达，而Bak基因表达量不变。RPMI 8226细胞用Fludarabine处理12小时，处理后细胞膜电位降低，61.05%的细胞表达低荧光罗丹明123，而未处理的对照组细胞仅为8.62%^[1]。为提高溶解度，Fludarabine可制为一磷酸盐形式(F-ara-AMP, fudarabine)，在静脉滴注后即可即时、定量的从母核上去磷酸化。细胞内重磷酸化修饰导致Fludarabine-阿糖胞苷三磷酸（(F-ara-ATP）。该代谢产物抑制了DNA复制的几个关键过程，如DNA合成所需酶，比如核糖核酸还原酶，DNA引发酶，DNA聚合酶，具有3 ' - 5 '外切酶活性的脱氧核糖核酸聚合酶δ和ε和DNA连接酶^[2]。通过检测ICAM - 1的表达和IL - 8释放，表明Fludarabine还可以诱导前炎症刺激单核细胞的增加^[3]。Fludarabine对卵巢癌细胞系生长无影响，而它对黑色素瘤细胞系有明显的剂量依赖性抑制^[4]。Fludarabine诱导显著降低STAT - 1磷酸化，但不改变JAK 2活性。磷酸Fludarabine对三种STAT蛋白磷酸化影响不显着。Fludarabine（1.5mg）在处理2天后和7天后显著降低磷酸化STAT - 1和STAT-1总蛋白量^[5]。磷酸化JAK 2在处理后第2天变化不明显，处理后第7天的JAK表达明显受抑制。Fludarabine不影响其他STAT蛋白质，特异性抑制STAT - 1激活以降低血管平滑肌细胞体外增殖。^[5]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
Jeko-1	MljsSpVv[3Srb36gRZN{[Xl?	Ml\ENlAh\|ryP	NWe2Z2JiOjRiaB?=		M2PxZ4lvcGmkaYTzJIV5eHKnc4Ppc44hd2ZiSVTP	MornQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV7NEC3NVIoRjJ3OUSwO\|EzRC:jPh?=
MV-4-11	MkL0RZBweHSxc3nzJGF{e2G7	NWPBWoNjOi53IN88US=>	MojTOFghcA>?		NFPnfVZqdmS3Y3XzJIFxd3C2b4Ppd{B{dGmpaITsfS=>	NYfLRZY4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWxNVE2QDNpPkK1NVEyPTh\|PD;hQi=>
THP-1	NXS4N2JISXCxcITvd4l{KEG\|c3H5	Mon3Nk42KM7:TR?=	NEXibG41QCCq		MVjpcoR2[2W\|IHHwc5B1d3OrczDzcIlocHSueR?=	NH;UWHg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUGxNVU5Oyd-MkWxNVE2QDN:L3G+
MOLM 13	NE\xRmxCeG:ydH;zbZMhSXO\|YYm=	M335eVIvPSEQvF2=	NHLONpA1QCCq		M4HWN4lv\HWlZYOgZZBweHSxc3nzJJNtcWeqdHz5	NUXMOmFbRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWxNVE2QDNpPkK1NVEyPTh\|PD;hQi=>
KBM3/Bu2506	MUTBdI9xfG:\|aYOgRZN{[Xl?	NULl[IdbOi53IN88US=>	M3rsflQ5KGh?		NWWy[XIxcW6mdXPld{BieG:ydH;zbZMhe2yrZ3j0cJk>	MmP1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVzMUG1PFMoRjJ3MUGxOVg{RC:jPh?=
Nalm-6	M1SwOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWnJR\|UxRTF6IN88US=>	MnKyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVyNkGxNFEoRjJ3ME[xNVAyRC:jPh?=
Reh	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVfJR\|UxRTNyIN88US=>	MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTB4MUGwNUc,OjVyNkGxNFE9N2F-
U2937	MkX2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXfTcXF7UUN3ME2xOkDPxE1?	MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTB4MUGwNUc,OjVyNkGxNFE9N2F-
Mec-1	MlHpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlXqTWM2OO,:nkWwNEDPxE1?	MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTB4MUGwNUc,OjVyNkGxNFE9N2F-
RPMI-8226	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGmzfo1KSzVyPUWwNEDPxE1?	NXPjO2U5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWwOlEyODFpPkK1NFYyOTBzPD;hQi=>
Molt-4	NFv4XZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWXJR\|UxRTF6MDFOwG0>	NGr5eHA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUC2NVExOSd-MkWwOlEyODF:L3G+
Nalm-6-FluR	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXLFb3AxUUN3ME2yOVAh\|ryP	Mne2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVyNkGxNFEoRjJ3ME[xNVAyRC:jPh?=
Raji	MWHGeY5kfGmxbjDBd5NigQ>?	M1vrclPDqM7:TR?=	MYeyOE81QC95MjDo		NXvUVYY1cW6mdXPld{Bi[2O3bYXsZZRqd26\|IH;mJJA2OyxicE[zJIFv\CCyN{RCpC=>	M{Pa[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OUSwOlk2Lz5{NEm0NFY6PTxxYU6=
PBMC	MWHGeY5kfGmxbjDBd5NigQ>?	M2HDUVUxNzFyMDFOwG0>	M3LwW\|I1KGh?	NGLCNFFFVVOR	NW\xe4tXcW6qaXLpeJMhW1SDVEGgdIhwe3Cqb4L5cIF1cW:w	MlrRQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7MUG4O\|IoRjJ2OUGxPFczRC:jPh?=
MDA-231	NInBRWdHfW6ldHnvckBCe3OjeR?=	M4rKZ\|ExOCEQvF2=	MmnUNlQhcA>?	M1PZdGROW09?	Mn7k[IVkemWjc3XzJGlFVyCneIDy[ZN{cW:w	M{GxU\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OUGxPFczLz5{NEmxNVg4OjxxYU6=
624.38mel	NGftTmtHfW6ldHnvckBCe3OjeR?=	MkS3OVAh\|ryP	MmjSNlQhcA>?	MlXUSG1UVw>?	MX7k[YNz\WG\|ZYOgTWRQKGW6cILld5Nqd25?	NXrXSoM2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS5NVE5PzJpPkK0PVEyQDd{PD;hQi=>
MDA-231	MnPQSpVv[3Srb36gRZN{[Xl?	NVfMcmNtPTBvMkCwJO69VQ>?	MmD5NlQhcA>?	M{XBSmROW09?	NYHOOFVTcW6qaXLpeJMhUUSRIHHjeIl3cXS7IHnu[IVx\W6mZX70cJkhd2ZibWLORUBt\X[nbIO=	NGLofXc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEmxNVg4Oid-MkS5NVE5PzJ:L3G+
624.38mel	M{DEOGZ2dmO2aX;uJGF{e2G7	NWjaZpVpPTBvMkCwJO69VQ>?	NFPSW\|czPCCq	MmD0SG1UVw>?	NIHSTYlqdmirYnn0d{BKTE9iYXP0bZZqfHliaX7k[ZBmdmSnboTsfUBw\iCvUl7BJIxmfmWucx?=	NVWzUJFDRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS5NVE5PzJpPkK0PVEyQDd{PD;hQi=>
HMECs	MlL6SpVv[3Srb36gRZN{[Xl?	MUCxNFDDqM7:TdMg	NVHibIFMOzcEoHi=		NX7WWYp{cW6qaXLpeJMhUU[QzsRCpIFv\CCOUGOgbY5lfWOnZDDTWGFVOSCyaH;zdIhwenmuYYTpc44h[W6mIFnSSlEh\XiycnXzd4lwdg>?	NH3ab2w9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEKxNVMzPyd-MkSyNVE{Ojd:L3G+
HMECs	Mlv0SpVv[3Srb36gRZN{[Xl?	NHrqNGgyODEEoN88UeKh	MU[zOuKhcA>?		Mli5bY5pcWKrdIOgTWZP\|rIEoH3l[IlifGWmIIDoc5NxcG:{eXzheIlwdiCxZjDTWGFVOSCjbnSgV3RCXDNuIHL1eEBvd3Rib3[gV3RCXDJ?	MXy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDJzMUOyO{c,OjR{MUGzNlc9N2F-
BJAB	M3fuZWFxd3C2b4Ppd{BCe3OjeR?=	MlrCOeKh\|ryP	MUGyOEBp		NXW5SodocW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?=	MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDB3N{G0O{c,OjRyNUexOFc9N2F-
I-83	M3TvPWFxd3C2b4Ppd{BCe3OjeR?=	M4XNR\|XDqM7:TR?=	MkfxNlQhcA>?		MYHpcoR2[2W\|IHPlcIwh[XCxcITvd4l{	NVHrcVBlRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSwOVcyPDdpPkK0NFU4OTR5PD;hQi=>
NALM6	NXHwVHhvSXCxcITvd4l{KEG\|c3H5	NXH0V5lGPcLizszN	M3\sdlI1KGh?		NYmzTZNRcW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?=	NW\HTY9ZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSwOVcyPDdpPkK0NFU4OTR5PD;hQi=>
DU-145	Ml[5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIPXSWUxNTFyIN88[{9udA>?	MYW0PEBpyqB?		M3:2TIlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz	NWHRSnkyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO3N\|Q5OTVpPkKzO\|M1QDF3PD;hQi=>
Nalm-6	NGP4SFVHfW6ldHnvckBCe3OjeR?=	NEf2epkyOMLizszN	NEDKfYkyNzJxNDDo		M4DtPIlv\HWlZYOgZZV1d3CqYXf5	NIWz[5o9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{[4NVIzOyd-MkO2PFEzOjN:L3G+
Reh	NVf1Sm0zTnWwY4Tpc44hSXO\|YYm=	MnfTNVDDqM7:TR?=	NHfEcXoyNzJxNDDo		MoTxbY5lfWOnczDheZRweGijZ4m=	MnzaQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN4OEGyNlMoRjJ\|NkixNlI{RC:jPh?=
Nalm-6	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXrmVGxyUUN3MDFijNwyOOLCid88US=>	MYq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzZ6MUKyN{c,OjN4OEGyNlM9N2F-
Reh	M1vYbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NF;jeo5KSzVyIPMIwFEx6oDLzszN	Ml3BQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN4OEGyNlMoRjJ\|NkixNlI{RC:jPh?=
HEC1A	NFu0WHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mo\wNVAxNTVyMDFOwG0>	NF\xNGczPCCq		NYTuRo54cW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ?	M2PFXVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|NUm1Olk4Lz5{M{W5OVY6PzxxYU6=
AN3CA	MkmwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NG\CVGMyODBvNUCwJO69VQ>?	NWn4fHdWOjRiaB?=		M{DD[olvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz	NWHFdXUyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO1PVU3QTdpPkKzOVk2Pjl5PD;hQi=>
HEC50B	M17BSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1v2OVExOC13MECg{txO	NGS5[YUzPCCq		MYXpcohq[mm2czDj[YxtKGe{b4f0bEB{dGmpaITsfS=>	M13UZlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|NUm1Olk4Lz5{M{W5OVY6PzxxYU6=
HEC1A	NGn4XmFCeG:ydH;zbZMhSXO\|YYm=	MVmyNE8yODBizszN	NGW0VHAzPCCq		MljYbY5lfWOnczDhdI9xfG:\|aYOgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK=	MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzV7NU[5O{c,OjN3OUW2PVc9N2F-
AN3CA	Ml3rRZBweHSxc3nzJGF{e2G7	M3f2fFIxNzFyMDFOwG0>	NXrIVZpHOjRiaB?=		MUHpcoR2[2W\|IHHwc5B1d3OrczDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?=	NEH0Opo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{W5OVY6Pyd-MkO1PVU3QTd:L3G+
HEC50B	MXHBdI9xfG:\|aYOgRZN{[Xl?	NELVeIIzOC9zMECg{txO	NHL0TG0zPCCq		MYnpcoR2[2W\|IHHwc5B1d3OrczDzcIlocHSueR?=	MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzV7NU[5O{c,OjN3OUW2PVc9N2F-
EHEB	MVTBdI9xfG:\|aYOgRZN{[Xl?	MVO0NEDPxE1?	NH;O[ZQzPCCq		M4DXcYlv\HWlZYOgZZBweHSxc3nz	NF;vNYc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{S5O\|A4PSd-MkO0PVcxPzV:L3G+
A549	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGn5XlRKSzVyPUG1MlfDuTJwODFCuW0>	NIqwWHg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{O3O\|E6Oid-MkOzO\|cyQTJ:L3G+
A549 GAPDH-deficient	M3;6NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4PjZ2lEPTB;MUiuOeKyOi5\|INM1US=>	M3XiTFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|M{e3NVkzLz5{M{O3O\|E6OjxxYU6=
CLL	Mm[xRZBweHSxc3nzJGF{e2G7	MoL4NVAh\|ryPwrC=	MUGyOE06PiCq		MkLybY5lfWOnczDhdI9xfG:2aXOgZ4VtdCCmZXH0bC=>	NUGxW\|VYRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKyNFc3QDZpPkKyNlA4Pjh4PD;hQi=>
MEC1	M3nRTmFxd3C2b4Ppd{BCe3OjeR?=	NITncmQyODEEoN88US=>	Mkm0O\|IhcA>?		MXHpcoR2[2W\|IHHwc5B1d3OrczDzbYdvcW[rY3HueIx6	MmjjQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJzM{K5O\|MoRjJ{MUOyPVc{RC:jPh?=
U937	MX3BdI9xfG:\|aYOgRZN{[Xl?	M3vURVAvQCEQvF2=	M3jkWlQuPDhiaB?=		MV3pcoR2[2W\|IHHwc5B1d3OrczDzcIlocHSueR?=	MoC5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJyN{S3NFAoRjJ{MEe0O\|AxRC:jPh?=
U937	NGP1NXRCeG:ydH;zbZMhSXO\|YYm=	NYTkXYRPOSEQvF2=	NVjRN3pvQTZiaB?=		MojEbY5lfWOnczDhdI9xfG:\|aYOgd4xq\2i2bIm=	MV28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjB{M{WyN{c,OjJyMkO1NlM9N2F-
Daudi	M1v5d2Fxd3C2b4Ppd{BCe3OjeR?=	NVX3cXZSOjBizszN	NGfpN4w6PiCq		M{jXWIlv\HWlZYOgZZBweHSxc3nzJJNtcWeqdHz5	NGLleHI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkCyN\|UzOyd-MkKwNlM2OjN:L3G+
J45.01	MXHBdI9xfG:\|aYOgRZN{[Xl?	MUmxJO69VQ>?	Ml3iPVYhcA>?		MYDpcoR2[2W\|IHHwc5B1d3OrczDzcIlocHSueR?=	NFXLUog9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkCyN\|UzOyd-MkKwNlM2OjN:L3G+
RPMI 8226	M3jqRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYDw[XdHUUN3ME2yOU46yqEEsdMgN{44KM7:TR?=	MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTl2OEK2OEc,OjF7NEiyOlQ9N2F-
CEM	NYHnc4YyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4XnSmlEPTB;Mj60xsDDucLiMD60JO69VQ>?	MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTl2OEK2OEc,OjF7NEiyOlQ9N2F-
Raji	NETLfWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3vTdGlEPTB;MD60O:KhyrIEoECuNFQh\|ryP	NX23PW84RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG5OFgzPjRpPkKxPVQ5OjZ2PD;hQi=>
U937	NYLsZZlwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NICxWYJKSzVyPUCuNlTDqMLzwrCwMlA1KM7:TR?=	MWi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTl2OEK2OEc,OjF7NEiyOlQ9N2F-
K562	NUTjd4h{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mln6TWM2OD1yLkS0xsDDucLiMD6wOUDPxE1?	M1LkVVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzOUS4NlY1Lz5{MUm0PFI3PDxxYU6=
NALM-6	NFzMd\|JCeG:ydH;zbZMhSXO\|YYm=	NHHkXnAyOCEQvF5CpC=>	MUiyOEBp		NXfXWVNTcW6mdXPld{Bk\WyuIHHwc5B1d3OrczDzcIlocHSueR?=	M4HOZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzNkm5N\|g{Lz5{MU[5PVM5OzxxYU6=
JMV-3	MkSwRZBweHSxc3nzJGF{e2G7	NWXTfZd[OTBizszNxsA>	MXWyOEBp		NWPOdphncW6mdXPld{Bk\WyuIHHwc5B1d3OrczDzcIlocHSueR?=	M2fnZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzNkm5N\|g{Lz5{MU[5PVM5OzxxYU6=
EHEB	MWPGeY5kfGmxbjDBd5NigQ>?	MoT4OU02OCEQvF2=	NGrIVW4zPCCq		MnHw[IVkemWjc3XzJJAzOSCneIDy[ZN{cW:wIIPp[45q\mmlYX70cJk>	M3r2OFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzMU[4N\|kyLz5{MUG2PFM6OTxxYU6=
JVM-2	NH7vfGVHfW6ldHnvckBCe3OjeR?=	NFX2RmY{OCEQvF2=	M3HtVFI1KGh?		Mojy[IVkemWjc3XzJJAzOSCneIDy[ZN{cW:w	MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTF4OEO5NUc,OjFzNkizPVE9N2F-
KBM3/Bu2506	M13nWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGjYVmZKSzJyPUCuOlchyrWP	NIXEOVg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MEmzN\|UxQSd-MkC5N\|M2ODl:L3G+
KBM3/Bu2506	MnvxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlvxNE43KM7:TR?=	NWnkZo92OjRiaB?=		NHvwXVhqdmO{ZXHz[ZMhfGinIHPlcIwh\nKjY4Tpc44hcW5iUz3wbIF{\Q>?	MXy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODl\|M{WwPUc,OjB7M{O1NFk9N2F-
MDA-MB-231	MoTxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUHqfVNWUUN3ME20MlAh\|ryP	MnyzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjB2NEezPVAoRjJyNES3N\|kxRC:jPh?=
MCF-7	M4SxNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUTJR\|UxRTF3LkCg{txO	Ml\TQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjB2NEezPVAoRjJyNES3N\|kxRC:jPh?=
HLE-B3	NV76[4ZxTnWwY4Tpc44hSXO\|YYm=	M4\xPFI2KM7:TR?=	NF;KPZM1QCCq		MUPicI9kc3NiSV\OMe6{6oDVaX7keYNm\CCVVFHUNUBxcG:\|cHjvdplt[XSrb36gZY5lKEmGTzDlfJBz\XO\|aX;u	M1vMeFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyNEO1NVU5Lz5{MESzOVE2QDxxYU6=
K562	M1LVNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NXTv[WFyPzJiaB?=		NF7YfFVKSzVyPUOuN{BvVQ>?	NUn0[5ZxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkCzNFcyQThpPkKwN\|A4OTl6PD;hQi=>
BW-225	M1jqbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NF;hZW1KSzJyPUGuN\|chy5dzMPMIlljDqM7:TdMg	NHfOVZM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOE[2NVM5OCd-MUi2OlE{QDB:L3G+
OH-65	NWHtcmJET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2O3TmlEOjB;MT6zO{DEnzFy4pkSPOKh\|ryPwrC=	NVrkSXdzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUi2OlE{QDBpPkG4OlYyOzhyPD;hQi=>
GR-145	M2PGRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYfJR\|IxRTJwN{Sgx7chOTEkiKK4JEDPxE4EoB?=	MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDZ4MUO4NEc,OTh4NkGzPFA9N2F-
A549	NHfrW4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3HYW2lEOjB;NT60PEDEnyBzMPMIllgh\|ryPwrC=	M4qwWlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6Nk[xN\|gxLz5zOE[2NVM5ODxxYU6=
CaSki	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGXJeHlKSzJyPUGuN\|chy5diMUFijLI4KM7:TdMg	MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDZ4MUO4NEc,OTh4NkGzPFA9N2F-
ZMK-1	NUjKWZpFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHrST\|hKSzJyPUGuN\|chy5diMUFijLI3KM7:TdMg	M{HIZ\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6Nk[xN\|gxLz5zOE[2NVM5ODxxYU6=
SKW6.4	NFvoPI1CeG:ydH;zbZMhSXO\|YYm=	NGDCPGUxNjBzLUGwJO69VQ>?	M{XKTVI1NzR6IHi=		NVvnTFVPcW6mdXPld{Bk\WyuIHTlZZRpKGmwIHLveIghfGmvZT2gZY5lKGSxc3WtJIRmeGWwZHXueEBu[W6wZYK=	NUXnSIhkRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUiwPVI{PDBpPkG4NFkzOzRyPD;hQi=>
RPMI 8226	Ml3TS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MkfSNlQhcA>?		MmXuTWM2OD1zLkW0xsDPxE1?	Mk\UQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTd7N{[xPFYoRjF5OUe2NVg3RC:jPh?=
MM.1S	NWjyUVNRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NVewcXdLPDhiaB?=		Mm\QTWM2OD1zMz60POKh\|ryP	MmHkQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTd7N{[xPFYoRjF5OUe2NVg3RC:jPh?=
MM.1R	NXrTWVNUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M3zPb\|Q5KGh?		MmfPTWM2OD1\|Mz63PUDPxE1?	Ml\OQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTd7N{[xPFYoRjF5OUe2NVg3RC:jPh?=
U937	M{XySGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWDmcmlGUUN3ME2zMFIxOCEEsTC1OlAhdk1?	MYW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPTl\|MEO2NUc,OTV7M{CzOlE9N2F-
CLL5	MlexRY51cXS3bX;yJIF{e2G7		MUK0PEBpenN?		MYDBcpRqfHWvb4KgZYN1cX[rdImgZYdicW6\|dDDDUGw2KGOnbHzzJIl{d2yjdHXkJIZzd21iQ1zMJJBifGmnboSgZZN{\XO\|ZXSgZZMh[2WubDD2bYFjcWyrdImgZYZ1\XJiNEigbJJ{KGK7IF\BR3Mh[W6jbInzbZMtKEWFNUCgQUAxNjF4IN88UU4>	M{nB[VxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NkezO\|M6Lz5{NE[3N\|c{QTxxYU6=
K562	MUTDfZRwfG:6aXPpeJkh[XO\|YYm=		NVW5WIRuPzJiaILz		MkDuR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gdIFkdGm2YYjlcE1z\XOrc4ThcpQhUzV4MjDj[YxteyCjZoTldkA4OiCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwJF0hOC5{NjFOwG0v	MnezQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjB4MEW2OVYoRjJyNkC1OlU3RC:jPh?=
CLL3	NXPSVXBySW62aYT1cY9zKGG\|c3H5		NEHl[pk1QCCqcoO=		M32ybmFvfGm2dX3vdkBi[3Srdnn0fUBi\2GrboP0JGNNVDNiY3XscJMhcXOxbHH0[YQh\nKxbTDDUGwheGG2aXXueEBie3Onc4Pl[EBieyClZXzsJJZq[WKrbHn0fUBi\nSncjC0PEBpenNiYomgSmFEWyCjbnHsfZNqeyxiRVO1NEA:KDBwM{Wg{txONg>?	NF\PVGs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NE[3N\|c{QSd-MkS2O\|M4Ozl:L3G+
CLL4	NHLO[2hCdnSrdIXtc5Ih[XO\|YYm=		MVy0PEBpenN?		NVrQN2FNSW62aYT1cY9zKGGldHn2bZR6KGGpYXnud5QhS0yONDDj[YxteyCrc3;sZZRm\CCocn;tJGNNVCCyYYTp[Y51KGG\|c3Xzd4VlKGG\|IHPlcIwhfmmjYnnsbZR6KGGodHXyJFQ5KGi{czDifUBHSUOVIHHuZYx6e2m\|LDDFR\|UxKD1iMD62OEDPxE1w	M1HzSVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NkezO\|M6Lz5{NE[3N\|c{QTxxYU6=
CEM-DNR-B	MWXDfZRwfG:6aXPpeJkh[XO\|YYm=		M4nsWFczKGi{cx?=		NFW5UmJEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBETU1vRF7SMWIh[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IF3UWEBie3OjeTygTWM2OCB;IEGuNFEh\|ryPLh?=	MneyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjB4MEW2OVYoRjJyNkC1OlU3RC:jPh?=
primary CLL	NFvMUJREgXSxdH;4bYNqfHliYYPzZZk>				NYnvTG06S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4heHKrbXHyfUBEVExiY3XscJMtKEyGNUCgQUAyNjFizszNMi=>	NFHHR\|c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUG0PFM6Oid-MkWxOFg{QTJ:L3G+
CLL6	MVTBcpRqfHWvb4KgZZN{[Xl?		MVO0PEBpenN?		NVj1dVlESW62aYT1cY9zKGGldHn2bZR6KGGpYXnud5QhS0yONjDj[YxteyCrc3;sZZRm\CCocn;tJGNNVCCyYYTp[Y51KGG\|c3Xzd4VlKGG\|IHPlcIwhfmmjYnnsbZR6KGGodHXyJFQ5KGi{czDifUBHSUOVIHHuZYx6e2m\|LDDFR\|UxKD1iMT62JO69VS5?	MnXVQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR4N{O3N\|koRjJ2NkezO\|M6RC:jPh?=
CLL2	MoX6RY51cXS3bX;yJIF{e2G7		MoewOFghcHK\|		M{DXOGFvfGm2dX3vdkBi[3Srdnn0fUBi\2GrboP0JGNNVDJiY3XscJMhcXOxbHH0[YQh\nKxbTDDUGwheGG2aXXueEBie3Onc4Pl[EBieyClZXzsJJZq[WKrbHn0fUBi\nSncjC0PEBpenNiYomgSmFEWyCjbnHsfZNqeyxiRVO1NEA:KDJwNk[g{txONg>?	M3HrcFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NkezO\|M6Lz5{NE[3N\|c{QTxxYU6=
HCT116	M2nGSWN6fG:2b4jpZ4l1gSCjc4PhfS=>		M1jyVFczKGi{cx?=		NGjoRW9EgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBJS1RzMU[gZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KFOUQjDhd5NigSxiSVO1NEA:KDZwNjFOwG0v	NWfnW\|VYRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW0OlIzPzdpPkK1OFYzOjd5PD;hQi=>
PBMC	NInRT3lEgXSxdH;4bYNqfHliYYPzZZk>		M1fN[FQ5KGi{cx?=		Ml3GR5l1d3SxeHnjbZR6KGGpYXnud5QheGG2aXXueEBRSk2FIHHmeIVzKDR6IHjyd{BjgSCFZXzsWIl1emVvQnz1[UBie3OjeTDpckBxemW\|ZX7jJI9nKG2xdYPlJG0zOTCENDDj[YxteyxiSVO1NEA:KDFyIN88UU4>	MnXUQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV3NkK0NVcoRjJ3NU[yOFE4RC:jPh?=
CHO	Mnj2SpVv[3Srb36gZZN{[Xl?				MlPMRolv\GmwZzDh[oZqdmm2eTDk[ZRmem2rbnXkJIJ6KGSrc4DsZYNmdWWwdDDv[kB{eGWlaX\pZ{BjcW6maX7nJI9nKFtzMkXJYW4uMDRvYX3pco8uOy2rb3TvdIhmdmW2aInsLU1i\GWwb4PpcoUhcW5ibXXtZpJidmW\|IH;mJGNJVyClZXzsd{B{fGGkbImgeJJidnOoZXP0[YQhf2m2aDD0bIUhemG2IHHk[Y5we2mwZTDBN{Bz\WOncITvdkwhU2liPTCxNE41KM7:TT6=	MoHIQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwPzdyN{OyNEc,PzdyN{OyNFww[T5?
JVM2	M2nRcmFvfGm2dX3vdkBie3OjeR?=				NIGwOmNCdnSrdIXtc5Ih[WO2aY\peJkh[WejaX7zeEBpfW2jbjDKWm0zKGOnbHzzJIF{e2W\|c3XkJIF{KGOnbHygeoli[mmuaYT5JIFnfGW{IES4JIhzeyCkeTDGRWNUKGGwYXz5d4l{NCCHQ{WwJF0hOTBwNDFOwG0v	M4juS\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NkezO\|M6Lz5{NE[3N\|c{QTxxYU6=
HeLa	NEf2N4VCdnSrdIXtc5Ih[XO\|YYm=				NWfxW5VnSW62aYT1cY9zKGGldHn2bZR6KGGpYXnud5QhcHWvYX6gTIVN[SClZXzsd{Bie3Onc4Pl[EBieyClZXzsJJZq[WKrbHn0fUBjgSCPVGSgZZN{[XluIFXDOVAhRSBzNjFOwG0v	NGjodZU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NE[3N\|c{QSd-MkS2O\|M4Ozl:L3G+
CLL1	M3LIbmFvfGm2dX3vdkBie3OjeR?=		MoTaOFghcHK\|		M1vXUWFvfGm2dX3vdkBi[3Srdnn0fUBi\2GrboP0JGNNVDFiY3XscJMhcXOxbHH0[YQh\nKxbTDDUGwheGG2aXXueEBie3Onc4Pl[EBieyClZXzsJJZq[WKrbHn0fUBi\nSncjC0PEBpenNiYomgSmFEWyCjbnHsfZNqeyxiRVO1NEA:KDF5LkGg{txONg>?	MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDZ5M{ezPUc,OjR4N{O3N\|k9N2F-
CEM	M4juRmN6fG:2b4jpZ4l1gSCjc4PhfS=>		M1H5eVczKGi{cx?=		MkfFR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gR2VOKGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDNWHQh[XO\|YYmsJGlEPTBiPTCxPU41QSEQvF2u	MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODZyNU[1Okc,OjB4MEW2OVY9N2F-
T47D	MXvDfZRwfG:6aXPpeJkh[XO\|YYm=		MnfpO\|IhcHK\|		NIjzV2VEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBVPDeGIHPlcIx{KGGodHXyJFczKGi{czDifUBUWkJiYYPzZZktKEmFNUCgQUA1Pi5{IN88UU4>	M4rzPVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NE[yNlc4Lz5{NUS2NlI4PzxxYU6=
A549	NWPMclBPS3m2b4TvfIlkcXS7IHHzd4F6		NGHqNFE4OiCqcoO=		MXXDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDBOVQ6KGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDNWHQh[XO\|YYmsJGlEPTBiPTC0O{41PCEQvF2u	NGDSc\|k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{ME[wOVY2Pid-MkC2NFU3PTZ:L3G+
CCRF-CEM	NXHPdnRtTnWwY4Tpc44h[XO\|YYm=	MoLFNVAhfU1?	MYmxJJRwKDZyIH3pcpM>		MVfEdpVoKHS{YX7zdI9zfCCrbjDoeY1idiCFQ2LGMWNGVSClZXzsd{Bie3Onc4Pl[EBieyCHTmSxMY1m\GmjdHXkJJVxfGGtZTDheEAyOCC3TTDh[pRmeiBzIITvJFYxKG2rboOgZpkhdGmzdXnkJJNkcW62aXzsZZRqd25iY3;1cpRqdmdiYX7hcJl{cXN?	NETXSY09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{O4PFcxPSd-MkOzPFg4ODV:L3G+
TC32	NUTaPIVXeUiWUzDhd5NigQ>?				MXTxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhXEN\|MjDj[Yxtew>?	MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
U-2 OS	NWW5eGp1eUiWUzDhd5NigQ>?				M1HlbJFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCXLUKgU3Mh[2WubIO=	NH\ySZM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
A673	M1XTTJFJXFNiYYPzZZk>				NIrz[HpyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiQU[3N{Bk\Wyucx?=	NWKxRXdGRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
DAOY	MmfxdWhVWyCjc4PhfS=>				NYXONJZ{eUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IFTBU3kh[2WubIO=	NXTsNHM{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
Saos-2	MV\xTHRUKGG\|c3H5				MYLxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhW2Gxcz2yJINmdGy\|	NUDVc3B3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
BT-37	MlnydWhVWyCjc4PhfS=>				NFn4SndyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiQmStN\|ch[2WubIO=	M{Lq[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
RD	NWnQW5JFeUiWUzDhd5NigQ>?				M4TYcpFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCURDDj[Yxtew>?	MWG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
SK-N-SH	NHHlSJVyUFSVIHHzd4F6				M3K5VZFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCVSz3OMXNJKGOnbHzz	NWLJW3NzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
MG 63 (6-TG R)	M2jzT5FJXFNiYYPzZZk>				NEfUN2RyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiTVegOlMhMDZvVFegVkkh[2WubIO=	M1;jXlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
BT-12	NH;LdHFyUFSVIHHzd4F6				M4T1bpFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCEVD2xNkBk\Wyucx?=	MmDxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
NB1643	MWTxTHRUKGG\|c3H5				M3qx[ZFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCQQkG2OFMh[2WubIO=	M{fDPFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
OHS-50	M{f2[5FJXFNiYYPzZZk>				Mn\ndWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKE:KUz21NEBk\Wyucx?=	NVG4fYR[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
BT-12	MoG4dWhVWyCjc4PhfS=>				NFfMVlZyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCFb37mbZJu[XSxcomgd4Nz\WWwIH\vdkBDXC1zMjDj[Yxtew>?	MknpQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
LAN-5	MUjxTHRUKGG\|c3H5				NVXjfpRSeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiQ3;u[olzdWG2b4L5JJNkemWnbjDmc5IhVEGQLUWgZ4VtdHN?	NXj6U4pXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
NB-EBc1	NU\xb3I6eUiWUzDhd5NigQ>?				M{no[ZFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KEOxbn\pdo1ifG:{eTDzZ5Jm\W5iZn;yJG5DNUWEY{GgZ4VtdHN?	M{nyU\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
SK-N-SH	NEHuV\|JyUFSVIHHzd4F6				NHLrbHRyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCFb37mbZJu[XSxcomgd4Nz\WWwIH\vdkBUUy2QLWPIJINmdGy\|	M2PsfVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
Rh41	NUXSO40zeUiWUzDhd5NigQ>?				NGjLWnhyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiUni0NUBk\Wyucx?=	MYC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
A673	NXnqeXEyeUiWUzDhd5NigQ>?				NFLa[mxyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCFb37mbZJu[XSxcomgd4Nz\WWwIH\vdkBCPjd\|IHPlcIx{MQ>?	Ml:zQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
BT-37	M4jnN5FJXFNiYYPzZZk>				M3rQV5FJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KEOxbn\pdo1ifG:{eTDzZ5Jm\W5iZn;yJGJVNTN5IHPlcIx{	NVO2T4o4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
MG 63 (6-TG R)	NFnMVJZyUFSVIHHzd4F6				M3jjUpFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KEOxbn\pdo1ifG:{eTDzZ5Jm\W5iZn;yJG1IKDZ\|IDi2MXRIKFJrIHPlcIx{	M{X5dFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
Rh30	MWjxTHRUKGG\|c3H5				NV\BPG8zeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiQ3;u[olzdWG2b4L5JJNkemWnbjDmc5IhWmh\|MDDj[Yxtew>?	NV;WU5VyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
U-2 OS	NVzkZYZVeUiWUzDhd5NigQ>?				NYLRV5JjeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiQ3;u[olzdWG2b4L5JJNkemWnbjDmc5IhXS1{IF;TJINmdGy\|	MmXwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
OHS-50	M2DsPJFJXFNiYYPzZZk>				NY\RflJ1eUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiQ3;u[olzdWG2b4L5JJNkemWnbjDmc5IhV0iVLUWwJINmdGy\|	M4HKRVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
SK-N-SH	M{i5fJFJXFNiYYPzZZk>				M4DXcZFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KE:{dHjv[49v[WxiM1Sgeoli[mmuaYT5JJNkemWnbjDmc5IhW0tvTj3TTEBk\Wyucx?=	M1G0U\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
RD	NEnrO5lyUFSVIHHzd4F6				NGjOXoFyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCFb37mbZJu[XSxcomgd4Nz\WWwIH\vdkBTTCClZXzsdy=>	NYLJeI9MRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
Daoy	NX\3N403eUiWUzDhd5NigQ>?				MoTYdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohV3K2aH;nc45idCB\|RDD2bYFjcWyrdImgd4Nz\WWwIH\vdkBF[W:7IHPlcIx{	NV\RZYVKRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
TC32	MlfudWhVWyCjc4PhfS=>				NGjTPXZyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCRcoToc4dwdmGuIEPEJINie3Cjc3Wgd4Nz\WWwIH\vdkBVSzN{IHPlcIx{	NF3pdFY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
TC32	NIjnb\|JyUFSVIHHzd4F6				M{fyZ5FJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KE:{dHjv[49v[WxiM1Sgeoli[mmuaYT5JJNkemWnbjDmc5IhXEN\|MjDj[Yxtew>?	MoPJQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
MG 63 (6-TG R)	NHnHUplyUFSVIHHzd4F6				MmHTdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohV3K2aH;nc45idCB\|RDD2bYFjcWyrdImgd4Nz\WWwIH\vdkBOTyB4MzCoOk1VTyCUKTDj[Yxtew>?	M4WxclxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
SJ-GBM2	MYHxTHRUKGG\|c3H5				MYDxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhW0pvR1LNNkBk\Wyucx?=	NUnRZlNGRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
SK-N-MC	Mn;DdWhVWyCjc4PhfS=>				MWDxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhW0tvTj3NR{Bk\Wyucx?=	NWG3Vo9uRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
NB-EBc1	MWrxTHRUKGG\|c3H5				MnPwdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKE6ELVXCZ\|Eh[2WubIO=	MnLRQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
LAN-5	NWKwcXh7eUiWUzDhd5NigQ>?				M2rqRpFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCOQV6tOUBk\Wyucx?=	NITmNFc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
Rh18	M4\zVpFJXFNiYYPzZZk>				M2jYfJFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCUaEG4JINmdGy\|	M4C2[\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
NB1643	M131ZpFJXFNiYYPzZZk>				NHrjPY9yUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCFb37mbZJu[XSxcomgd4Nz\WWwIH\vdkBPSjF4NEOgZ4VtdHN?	NH61Z2I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
SK-N-MC	NVnSWotZeUiWUzDhd5NigQ>?				MVrxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBEd26oaYLtZZRwenlic3Py[YVvKG[xcjDTT{1PNU2FIHPlcIx{	M2HyR\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
SJ-GBM2	NIXPNotyUFSVIHHzd4F6				MnfBdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohS2:wZnnycYF1d3K7IIPjdoVmdiCob4KgV2ouT0KPMjDj[Yxtew>?	NFizSWo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
TC32	MYDxTHRUKGG\|c3H5				M4n0WpFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KEOxbn\pdo1ifG:{eTDzZ5Jm\W5iZn;yJHREOzJiY3XscJM>	MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
Rh18	MkDZdWhVWyCjc4PhfS=>				MUXxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBEd26oaYLtZZRwenlic3Py[YVvKG[xcjDSbFE5KGOnbHzz	M{OycFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
Saos-2	MV\xTHRUKGG\|c3H5				MUDxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBEd26oaYLtZZRwenlic3Py[YVvKG[xcjDTZY9{NTJiY3XscJM>	MlXSQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
SJ-GBM2	NVfm[G57eUiWUzDhd5NigQ>?				M1nO[JFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KE:{dHjv[49v[WxiM1Sgeoli[mmuaYT5JJNkemWnbjDmc5IhW0pvR1LNNkBk\Wyucx?=	NYTkeVh[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
RD	NWnSVG1LeUiWUzDhd5NigQ>?				NEfSVoxyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCRcoToc4dwdmGuIEPEJJZq[WKrbHn0fUB{[3KnZX6g[o9zKFKGIHPlcIx{	NYP2dnJ7RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	procaspase-9 / procaspase-3; PubMed: 27223263 Oncotarget Procaspase-9 and procaspase-3 were analyzed by Western blot in CLL cells from three patients after a 48 h-incubation in the absence or presence of 3 μM aphidicolin (APC) with or without fludarabine at 0.3 and 1 μM. β-Actin served as a loading control. p-p53 / p53; PubMed: 27223263 Oncotarget (A–B) CLL cells from 3 different patients were incubated for 24 h with fludarabine at the indicated concentrations in the absence or presence of 3 μM aphidicolin (APC). Phosphorylation of p53 at Ser-15 and total p53 were analyzed by Western blot. Data sho䲧疝Ỵ疞㧀疜膉痘 瘿�෋ᾰƌ෋à 㺣痖帉痖Ѐ瑖堘𢡄빢᎒෋à鑸᎒彿堙奋堙巫堙᎒ﻺ᎒彿堙ﻮ᎒ STAT1; PubMed: 26677135 Int J Mol Med Representative western blot analysis of STAT1 in RAW 264.7 cells treated with STAT1 inhibitor fludarabine (Flu) for 24 h.	27223263 26677135
Immunofluorescence	α-SMA / Vimentin; PubMed: 28322315 Sci Rep FLU (50 μM) reduces the expression of α-SMA and Vimentin protein in primary mouse activated HSCs (Hepatic Stellate Cells).	28322315
Growth inhibition assay	Cell viability ; PubMed: 24956101 PLoS One CLL cells RPMI/0.1% FBS were cultured on 0.5% BSA or 150 nM MMP-9 for 1 h prior to adding the indicated concentrations of fludarabine (Fluda). After 48 h (Fluda) cell viability was determined by flow cytometry using FITC-Annexin V and PI.	24956101

体内研究

PBS对照组中肿瘤细胞增长迅速，25天内扩增为10倍。而用40mg/kgFludarabine处理的肿瘤扩增不超过5倍。40mg/kgFludarabine对RPMI 8226细胞有明显的抗肿瘤效果。RPMI 8226处理肿瘤细胞十天后增加凋亡细胞核数量。^[1] Fludarabine可在免疫缺陷小鼠中有效抑制RPMI 8226细胞的骨髓转移。

细胞实验： ^[1]	- 合并 Cell lines: 地塞米松敏感(MM.1S) 和耐受 (MM.1R) 的人MM 细胞系, RPMI8226和 U266 细胞系 Concentrations: 2 μg/Ml Incubation Time: 24 小时 Method: 对地塞米松敏感(MM.1S) 和耐受 (MM.1R) 的人MM 细胞系, RPMI8226和 U266 细胞系以5 × 10⁵细胞密度铺板，实验组均包括氟达拉滨处理和空白对照组。处理后细胞用PBS清洗两次然后用70%冰乙醇固定，离心后用含100μg/mL核糖核酸酶PBS重悬浮，37ºC孵育30分钟。样品重悬于25μg/mL碘化吡啶中，用流式细胞仪检测。根据产品说明用Annexin V-FITC试剂盒检测细胞凋亡。利用TUNEL（末端脱氧核苷酸转移酶介导脱氧核苷酸缺口末端标记）法和原位细胞凋亡检测试剂盒处理细胞，最后用流式细胞仪分析。 (Only for Reference)
动物实验： ^[1]	- 合并 Animal Models: 携带RPMI 8226肿瘤细胞的免疫缺陷型小鼠 Dosages: 40 mg/kg Administration: 腹腔注射 (Only for Reference)

参考文献

- 合并

溶解度 (25°C)

体外	DMSO	57 mg/mL (199.83 mM)
	Water	Insoluble
	Ethanol	Insoluble
体内	从左到右依次将纯溶剂加入产品，现配现用(数据来自Selleck实验检测而非文献)： 5%DMSO+40%PEG300+5%Tween80+50%ddH2O	8 mg/mL

* 溶解度检测是由Selleck技术部门检测的，可能会和文献中提供的溶解度有所差异，这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据 Download Fludarabine (NSC 118218) SDF

分子量	285.23
化学式	C₁₀H₁₂FN₅O₄
CAS号	21679-14-1
储存条件	3年-20°C 粉状 2年-80°C 溶于溶剂
别名	FaraA, Fludarabinum

动物体内配方计算器 (澄清溶液)

第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量）

给药剂量

mg/kg

动物平均体重

每只动物给药体积

动物数量

只

第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系Selleck为您提供正确的澄清溶液配方）

% DMSO+ % + % Tween 80+ % ddH₂O

计算重置

计算结果:

工作液浓度： mg/ml；

DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，注：如该浓度超过该批次药物DMSO溶解度，请先联系Selleck）；

体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL ddH₂O，混匀澄清。

注意：1. 首先保证母液是澄清的；
2. 一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。

计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系，公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

质量

浓度

体积

分子量
=

×

×

*在配置溶液时，请务必参考Selleck产品标签上、SDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。

稀释计算器

用本工具协助配置特定浓度的溶液，使用的计算公式为：

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入输出 )

C1

V1

C2

V2
×

=

×

在配置溶液时，请务必参考Selleck产品标签上、SDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。.

连续稀释计算器方程

连续稀释
初始浓度:
稀释倍数:

计算结果

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

分子量计算器

通过输入化合物的化学式来计算其分子量：

注：化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量	浓度	体积	分子量
=	×	×
计算

临床试验信息 (data from https://clinicaltrials.gov, updated on 2021-05-17)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT04526795	Not yet recruiting	Drug: Cytarabine\|Drug: Fludarabine\|Drug: Pegcrisantaspase	Blast Phase Chronic Myelogenous Leukemia BCR-ABL1 Positive\|Recurrent Acute Biphenotypic Leukemia\|Recurrent Acute Lymphoblastic Leukemia\|Recurrent Acute Myeloid Leukemia\|Recurrent Chronic Myelogenous Leukemia BCR-ABL1 Positive\|Recurrent T-Cell Prolymphocytic Leukemia\|Refractory Acute Biphenotypic Leukemia\|Refractory Acute Lymphoblastic Leukemia\|Refractory Acute Myeloid Leukemia\|Refractory Chronic Myelogenous Leukemia BCR-ABL1 Positive\|Refractory T-Cell Prolymphocytic Leukemia	M.D. Anderson Cancer Center\|National Cancer Institute (NCI)	December 31 2020	Phase 1
NCT03832127	Not yet recruiting	Drug: 18F-Fludarabine	Myeloma	Nantes University Hospital\|Cyceron	April 1 2019	Phase 1
NCT03696537	Active not recruiting	Drug: Fludarabine\|Radiation: Total Marrow Irradiation (TMI)	Acute Myeloid Leukemia\|Chronic Myeloid Leukemia\|Acute Lymphocytic Leukemia\|Myelodysplastic Syndromes	Naoyuki G. Saito M.D. Ph.D.\|Indiana University	August 29 2018	Phase 1
NCT02718755	Withdrawn	Drug: Fludarabine\|Drug: Cytarabine\|Drug: Erwinase	Hematologic Malignancy	M.D. Anderson Cancer Center\|Jazz Pharmaceuticals	May 2018	Phase 2

技术支持

在订购、运输、储存和使用我们的产品的任何阶段，您遇到的任何问题，均可以通过拨打我们的热线电话400-668-6834，或者技术支持邮箱tech@selleck.cn，直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题，请给我们留言。

常见问题及建议解决方法

问题 1：
how to re-suspend and deliver the inhibitor for in vivo experiments?
回答：
For S1491, Fludarabine, we tested a vehicle: 30% Propylene glycol, 5% Tween 80, 65% D5W that you can resuspend the compound in at up to 30mg/ml. It's a suspension and can only be given via oral gavage.

研究领域

产品类型

定制您的化合物库

Fludarabine (NSC 118218)

客户使用Selleck生产的Fludarabine (NSC 118218)发表文献103篇：

产品安全说明书

STAT抑制剂选择性比较

生物活性

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

参考文献

溶解度 (25°C)

化学数据 Download Fludarabine (NSC 118218) SDF

动物体内配方计算器 (澄清溶液)

计算器

摩尔浓度计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

稀释计算器

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

连续稀释计算器方程

连续稀释

计算结果

分子量计算器

总分子量：g/mol

摩尔浓度计算器

临床试验信息 (data from https://clinicaltrials.gov, updated on 2021-05-17)

技术支持

常见问题及建议解决方法

STAT Signaling Pathway Map

相关STAT产品